Inovio’s INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Inovio Pharma (INO) Swings to Q3 Profit
November 9, 2015 6:28 AM ESTInovio Pharma (NASDAQ: INO) reported Q3 EPS of $0.07, versus ($0.12) reported last year. Revenue for the quarter came in at $24.18 million, versus $1.84 million reported last year.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
... MoreInovio Pharma (INO) Announces Interim Data Analyssis of INO-3112 in Patients With Head & Neck Cancer
November 5, 2015 9:01 AM ESTInovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses and was well tolerated in all evaluable patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18.
The immunology results show that INO-3112 generated robust HPV16/18 specific CD8+ T cell responses and antibodies against HPV16/18 in all 10 tested patients who received all treatments. These results will be presented today and tomorrow at the 30th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer in National... More
